

---

# Product Data Sheet

---

## Brilliant Violet 421™ anti-human CD38

**Catalog # /** 2585600 / 100 tests

**Size:** 2585595 / 25 tests

**Clone:** S17015A

**Isotype:** Mouse IgG1, κ

**Immunogen:** Human CD38 transfectants

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

**Workshop Number:** HCDM listed

**Concentration:** Lot-specific

□ Human peripheral blood lymphocytes were surface stained with anti-human CD19 FITC and anti-human CD38 (clone S17015A) Brilliant Violet 421™ (left) or mouse IgG1, κ Brilliant Violet 421™ isotype control (right).

## Applications:

**Applications:** Flow Cytometry

□ HLA-A2 negative human peripheral blood lymphocytes were stained with anti-human HLA-A2 (clone BB7.2) PE/Dazzle™ 594 (filled histogram) or mouse IgG2b, κ PE/Dazzle™ 594 isotype control (open histogram).

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** S17015A does not cross-block binding of clones HIT2, HB-7 or S17015F also raised against human CD38 based on in-house testing.

**Application References:**

1. Hildreth JE, *et al.* 1991. *Blood* 77:121. (IP, WB)
2. Beatty WL, *et al.* 2006. *J. Cell Sci.* 119:350. (IF)

---

**Description:** CD38 is a 45 kD type II transmembrane glycoprotein also known as T10. It is an ADP-ribosyl hydrolase expressed at variable levels on hematopoietic cells and in some non-hematopoietic tissues (such as brain, muscles, and kidney). In humans, it is expressed at high levels on plasma cells and activated T and B cells. By functioning as both a cyclase and a hydrolase, CD38 mediates lymphocyte activation, adhesion, and the metabolism of cADPR and NAADP. CD31 is the ligand of CD38.

**Antigen References:**

1. Ferrero E, *et al.* 1999. *J Leukoc Biol.* 65:151.
2. Lund F, *et al.* 1995. *Immunol Today.* 16:469.